CryoLife has enrolled the first patient in a US investigational device exemption trial for its BioFoam surgical matrix, designed for cellular aggregation and enhanced haemostasis.

BioFoam, a protein hydrogel biomaterial, will be used as an adjunct to achieve haemostasis on newly resected liver parenchyma.

The prospective, multicentre and randomised feasibility study will enrol 20 people, ten in each treatment group, to assess safety outcomes of BioFoam compared with a standard topical haemostatic agent.

The company also plans a follow-on pivotal study on successful completion of the feasibility study and subsequent US Food and Drug Administration and Department of Defence approvals.

The pivotal study will enrol a total of 164 people, 82 in each treatment group, and the data derived from it will be used to support a premarket approval application for BioFoam in the US.

The primary objective of the pivotal study will be to demonstrate a decrease in the time to achieve intraoperative haemostasis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.